Related by context. All words. (Click for frequent words.) 67 ENRICH trial 66 LibiGel Phase III 65 ongoing Phase IIIb 65 phase IIb clinical 64 SYMMETRY trial 64 BLA submission 64 Phase 2a trial 64 SUCCEED trial 63 MERLIN TIMI 63 rALLy trial 63 registrational 63 Anturol TM 63 Genasense R oblimersen 63 sNDA submission 63 CLIRS trial 62 Phase 2b study 62 PDX pralatrexate 62 Phase Ib study 62 pharmacokinetic PK 62 MAGE A3 ASCI 62 oral ridaforolimus 62 pivotal Phase III 62 Phase III clinical 62 Phase 2a clinical 62 Phase IIB 62 Special Protocol Assessment 62 Investigational Device Exemption 62 unblinded 62 Phase 1b trial 61 pivotal bioequivalence 61 pralatrexate 61 Zenvia Phase III 61 phase IIb trial 61 viral kinetic 61 randomized Phase 2b 61 PROVENGE sipuleucel T 61 placebo controlled Phase 61 bevirimat Study 61 multicenter Phase 61 Investigational Device Exemption IDE 61 BRIM3 61 confirmatory Phase 3 61 FOLOTYN ® 61 AIR CF1 61 Phase 2b trial 61 confirmatory clinical 61 Phase IIIb clinical 61 APEX AMI trial 61 efficacy endpoints 61 Fibrillex TM 61 ongoing Phase 1b 61 nonclinical studies 61 PEARL SC 61 Phase 2b clinical 60 PMA submission 60 EDEMA3 60 Phase III pivotal 60 placebo controlled Phase III 60 AVADO 60 pivotal Phase 60 Phase Ib 60 MEND CABG 60 clinical trial 60 ENDEAVOR IV 60 clinical pharmacology studies 60 ToGA 60 ADVANCE PD 60 randomized controlled multicenter 60 multicenter multinational 60 phase IIa clinical 60 AIR CF2 60 LUMINATE 60 lesinurad 60 PRECISE trial 60 Phase IIb 60 malignant mesothelioma Alfacell 60 ANCHOR trial 60 elotuzumab 60 phase IIb 60 COMFORT II 60 phase IIa 60 CRMD# 60 Dacogen injection 60 RSD# oral 60 dose escalation phase 60 alvimopan 60 Phase IIb III 59 multicenter Phase II 59 European Sepsis Trial 59 Phase III confirmatory 59 confirmatory Phase III 59 NEO3 59 Zenvia ™ 59 Board DSMB 59 Phase IIIb study 59 AVERROES 59 Urocortin 2 59 thorough QT 59 Aurexis 59 UVIDEM 59 trastuzumab emtansine T DM1 59 CIP TRAMADOL ER 59 BLA filing 59 ponatinib 59 EOquin TM 59 INCB# [001] 59 Phase #b/#a 59 NO# [002] 59 Anturol 59 OvaRex ® MAb 59 PFO migraine 59 multicenter Phase III 59 EDEMA4 59 talactoferrin 59 Phase IIa trial 59 sodium Injection 59 TELCYTA 59 randomized Phase IIb 59 Phase IIb clinical 59 Proellex TM 59 Stedivaze 59 CIMZIA ™ 59 PIX# [002] 59 Ganite ® 59 EDEMA3 trial 59 phase IIIb 59 ThermoDox ® clinical 59 Phase Ia 59 PRIMO CABG2 59 trastuzumab DM1 T DM1 59 Augment Injectable 59 KRN# 59 randomized Phase III 59 retrospective observational study 58 Resolute DES 58 Zerenex 58 GAMMAGARD 58 phase Ib 58 AVOREN 58 randomized Phase 58 PRECISE Trial 58 dose cohort 58 Phase IIa clinical 58 Allovectin 7 ® 58 Prostate AdenoCarcinoma Treatment 58 BCIRG 58 NEBIDO 58 Genasense ® oblimersen 58 HCV RESPOND 2 58 EFAPROXYN 58 Phase 2a 58 interferon gamma 1b 58 Onrigin TM 58 huC# DM4 58 FavId 58 phase IIb study 58 Onrigin 58 PANVAC VF 58 GENASIS trial 58 EMPOWER ™ 58 multicenter clinical 58 EmbraceAC 58 Phase III 58 KNS # 58 Phase III psoriasis 58 STRIDE PD 58 severe hypercholesterolemia 58 IMPACT DCM 58 Phase #/#a trial 58 adjuvant GIST 58 Phase #/#a 58 Phase 2b kidney transplant 58 MEND CABG II 58 RE LY ® 58 RHUCIN 58 formal pharmacokinetic PK 58 pharmacokinetic studies 58 FOLOTYN 58 prospectively defined 58 unblind 58 MIST II 58 Phase IIb clinical trials 58 TOLAMBA 58 Phase III VISTA 58 COU AA 58 DSMB 58 Phase Ib clinical trials 58 CLARITY study 58 oxymorphone ER 58 MAA submission 58 FAME Study 58 Phase 1b 58 ASCEND HF 58 prospective observational 58 Dose escalation 58 Medidur TM FA 58 neratinib 58 CIP ISOTRETINOIN 58 Virulizin R 58 Azedra 58 UPLYSO 57 PRIMO CABG 57 L MTP PE 57 DASISION 57 bepotastine besilate nasal spray 57 torezolid phosphate 57 Rasilez Tekturna 57 Phase 1b clinical 57 lucinactant 57 dose escalation Phase 57 R# #mg BID 57 CINQUIL 57 BioNumerik 57 BRIM2 57 MOZOBIL 57 Committee IDMC 57 registrational trial 57 EVEREST II 57 multiple ascending dose 57 ABSORB trial 57 Phase Ib II 57 GATTEX ® 57 ISTODAX 57 peginesatide 57 OPT CHF 57 CoFactor 57 Tarceva TM 57 Phase IIIb 57 COSIRA trial 57 Octreolin 57 budesonide MMX Phase III 57 metastatic HRPC 57 Matrix Phase 2b 57 Phase 1b clinical trials 57 Maximum Tolerated Dose MTD 57 modified REGENESIS Phase IIb 57 PLCO 57 lintuzumab 57 randomized controlled Phase 57 phase IIb III 57 exemption IDE 57 REVIVE Diabetes 57 brivaracetam 57 HGS ETR1 57 HORIZONS AMI trial 57 Veronate 57 ThermoDox R 57 budesonide foam 57 Zemplar Capsules 57 Phase IIa trials 57 GetGoal Phase III 57 Phase 1a clinical 57 dosing cohort 57 mg/m2 cohort 57 dose escalation 57 Genasense ® 57 APEX AMI 57 GSK# [001] 57 refractory Hodgkin lymphoma 57 nonrandomized 57 CAMMS# 57 Thorough QT 57 NATRECOR ® 57 BR.# 57 randomized multicenter Phase III 57 pharmacokinetic PK study 57 designated HVTN 57 lorcaserin Phase 57 Phase #b/#a clinical 57 oral calcitonin 57 ENDEAVOR III 57 Phase IIb trial 57 ganetespib 57 EchoCRT 57 Phase Ib clinical 57 indiplon capsules 57 AzaSite Plus 57 PERSEUS 57 tolerated dose MTD 57 IIa trial 57 #D#C# 57 PEG PAL 57 ARCOXIA 57 Phase IIa clinical trials 57 elagolix 57 oral taxane 57 LEUKINE 57 clinical trials 56 dacetuzumab 56 Triolex 56 GLP toxicology studies 56 REVLIMID lenalidomide 56 CARE HF 56 NP2 Enkephalin 56 Tanespimycin 56 urocortin 2 56 Sulonex TM 56 dose escalation clinical 56 multicenter placebo controlled 56 Phase III metastatic melanoma 56 PROTECT II 56 Omigard 56 Plicera 56 Androxal TM 56 assessing T DM1 56 AZX# 56 Raptiva ® 56 BrachySil TM 56 tolevamer 56 BrachySil 56 oral deforolimus 56 Silenor NDA 56 SILENOR TM 56 Cloretazine R VNP#M 56 EMPHASIS HF trial 56 Inc. NASDAQ AVNR 56 double blinded placebo 56 ruxolitinib 56 unresectable malignant mesothelioma UMM 56 placebo controlled clinical trials 56 successfully commercialize Iluvien 56 OLEPTRO TM 56 postapproval 56 blinded randomized placebo controlled 56 phase III isavuconazole 56 placebo controlled clinical 56 ICA # 56 maximally tolerated dose 56 IND submission 56 REALITY Trial 56 eprodisate KIACTA TM 56 SPIRIT IV 56 evaluable subjects 56 IL# PE#QQR 56 IMPACT IMmunotherapy 56 serum phosphorous 56 IND Investigational New 56 secondary efficacy endpoints 56 DAPT Study 56 ADAGIO study 56 treatment naive genotype 56 PROTECT AF 56 crizotinib PF # 56 APEX PD 56 Phase IIa 56 ENESTnd 56 clinical endpoints 56 CHAMPION PCI 56 EXPLORE Xa 56 Nasdaq MAPP 56 Proxinium TM 56 opioid induced bowel dysfunction 56 Hedgehog Pathway Inhibitor 56 PI3K/Akt pathway inhibitor 56 Phase III clinical trials 56 vosaroxin 56 MGN# 56 IMA# 56 AIR CF3 56 RE LY 56 bicifadine 56 REVIVE TA 56 Ophena TM 56 axitinib 56 forodesine 56 OvaRex R 56 Phase III multicenter 56 MYTHOS trial 56 randomized discontinuation trial 56 blinded randomized 56 evaluating tivozanib 56 Pharmacokinetic parameters 56 prGCD 56 CURE AF 56 OncoVEX GM CSF 56 AZILECT R 56 Ixempra 56 CCX# 56 Primary endpoints 56 intravenous methylnaltrexone 56 PREZISTA r 56 Rhucin ® 55 granted Ortec 55 lomitapide 55 zileuton CR 55 SinuNase TM 55 HGS ETR2 55 PHX# 55 NSABP C 55 masked placebo controlled 55 ELACYT 55 ALN VSP Phase 55 midstage trials 55 bardoxolone 55 PRECiSE 55 ATL# [001] 55 INTERCEPT platelets 55 PrevOnco 55 tramiprosate Alzhemed TM 55 ularitide 55 NATRECOR R 55 ospemifene 55 lintuzumab SGN 55 MGCD# [001] 55 IMPACT DCM clinical 55 MelaFind pivotal 55 dose cohorts 55 perifosine KRX 55 bazedoxifene 55 TRISENOX 55 fidaxomicin Phase 3 55 compound CIP FENOFIBRATE 55 nalbuphine ER 55 Viprinex TM 55 Nasdaq PPHM 55 ONTARGET 55 ZEGERID Capsules 55 ELND# 55 PARTNER Trial 55 Ganite R 55 SNT MC# 55 IMPROVE HF 55 drug eluting coronary stent 55 Xcellerated T Cells 55 Anturol ® 55 Hepatocellular Carcinoma HCC 55 vernakalant oral 55 Zevalin consolidation 55 MADIT II 55 Nasdaq OPTR 55 Orathecin 55 GTC recombinant human 55 R#/MEM # 55 IMPROVE IT 55 intravesical infusion therapy 55 THALOMID 55 hoFH 55 GEM OS1 55 alvespimycin 55 CALGB # [002] 55 RenalGuard System TM 55 FDA Investigational Device 55 LibiGel ® 55 denufosol 55 TOCOSOL Paclitaxel 55 Cethrin 55 Pivotal Trial 55 MEK Inhibitor 55 Amrubicin 55 CLL8 55 Pre RELAX AHF 55 active comparator 55 PROMACTA 55 preclinical pharmacokinetic 55 relapsed refractory multiple myeloma 55 virus HCV protease inhibitor 55 XL# XL# XL# 55 BEMA Granisetron 55 Phenoptin 55 Icatibant 55 Phase 1b dose escalation 55 NCT# ClinicalTrials.gov 55 Phase 1a 55 recurrent metastatic ovarian cancer 55 Aflibercept 55 ACCLAIM trial 55 Pirfenidone 55 phase Ib clinical 55 PS# [001] 55 subgroup analyzes 55 QNEXA 55 iPrEx 55 CHAMPION PLATFORM 55 pseudobulbar affect PBA 55 dirucotide 55 riociguat 55 eosinophilic asthma 55 phase 2a 55 LibiGel ® testosterone gel 55 methylnaltrexone 55 prospective randomized multicenter 55 Neuradiab 55 ENDEAVOR II 55 Maximum Tolerated Dose 55 SABCS 55 Biologic License Application BLA 55 IIb clinical trial 55 midstage clinical 55 omecamtiv mecarbil 55 evaluating bafetinib 55 dose escalation trial 55 Targretin capsules 55 Xcytrin R 55 novel antifolate currently 55 MEK inhibitor RDEA# 55 SPIRIT FIRST 55 teduglutide 55 Traficet EN 55 Pixuvri 55 pharmacodynamic PD 55 YONDELIS 55 Cinryze TM 55 CR# vcMMAE 55 dose escalation study 55 unblinding 55 Testosterone MDTS ® 55 deforolimus 55 Tumor Response 55 Allovectin 7 R 55 TITLE Auctions 55 ascending dose 55 Pivotal Phase III 55 Combidex 55 refractory chronic lymphocytic 55 prospective randomized placebo 55 RIGScan CR 55 ELADUR 55 RAPTIVA 55 Sorafenib HCC Assessment 55 DSMB recommended 55 enzastaurin 55 budesonide MMX 55 double blinded randomized 55 PREGNANT Study 55 asthma immunotherapeutic 55 sulodexide 55 TRA 2P 54 PREOS 54 GED aPC 54 galiximab 54 Group B CALGB 54 SIMPADICO 54 azficel T 54 ALN VSP 54 Entereg R 54 PROVENGE ® 54 SAR# [004] 54 dextofisopam 54 Prostate Lung Colorectal 54 memantine HCl 54 HspE7 54 custirsen 54 rALLy 54 danoprevir 54 OMAPRO ™ 54 randomized multicenter 54 Chrysalin 54 Nasdaq PGNX today 54 prospective multicenter randomized 54 ExTRACT TIMI 54 Phase Ib IIa 54 Intermezzo ® NDA 54 TAXUS Element Stent System 54 AMPAKINE CX# 54 Asentar 54 SPIRIT III 54 Drug Eluting Stent System 54 Clinical Trials Agreement 54 Elagolix 54 OAB overactive bladder 54 IoGen 54 oxybutynin ATD TM 54 GALNS 54 preclinical efficacy 54 BEMA Buprenorphine 54 IND CTA 54 LymphoStat B Phase 54 oral rivaroxaban 54 anticancer compound 54 ASSERT trial 54 PROPEL 54 Actimmune ® 54 Ceflatonin ® 54 Exelbine NDA 54 Troxatyl 54 PRNewswire FirstCall Genta Incorporated 54 PROSTVAC TM 54 trastuzumab DM1 54 RELOVAIR ™ 54 MoxDuo IR 54 Prosaptide 54 PIX# trial 54 relapsed MCL 54 TACI Ig 54 AEGR 54 Panzem R NCD 54 Phase 2b 54 TYZEKA 54 PROactive study 54 bile duct tumor 54 balsalazide tablet 54 Mylotarg 54 randomized blinded 54 elacytarabine 54 phase III ACCLAIM 54 dalbavancin 54 Phase III TRIST 54 SILENOR 54 valopicitabine 54 plasma pharmacokinetics 54 ridaforolimus 54 StemEx 54 Premarket Approval PMA 54 Ereska 54 evaluating REVLIMID 54 number NCT# ClinicalTrials.gov 54 unique alkylating agent 54 Phase 2b randomized 54 NeuroFlo 54 Tekturna HCT 54 Carotid Revascularization Endarterectomy vs. 54 INSPIRE Trial Phase III 54 PRESEPT 54 PRTX 54 lorcaserin NDA 54 eprotirome 54 CANCIDAS 54 Triapine R 54 CoreValve System 54 GENASIS clinical 54 rALLy clinical trial 54 Oracea TM 54 Diamyd ® 54 Val HeFT 54 TAXUS VI 54 LibiGel NDA 54 Besivance 54 FACTIVE R gemifloxacin 54 dexanabinol 54 Phase III ADT 54 pegloticase 54 LymphoStat B TM 54 EXPAREL ™ 54 HER2 positive metastatic breast 54 Somatuline R Autogel R 54 Pivotal Clinical Trial 54 Phase III placebo controlled 54 AIM HIGH 54 REG1 Anticoagulation System 54 LymphoStat B 54 substudy 54 please visit www.advaxis.com 54 ancrod 54 compound INCB# 54 acyclovir Lauriad R 54 placebo controlled randomized 54 Virulizin ® 54 multicenter randomized clinical 54 Screening Trial 54 Exelixis compounds 54 Panzem R 54 Hematide ™ 54 Jack Pirozzolo 54 NEUMUNE 54 Phase III HEAT 54 Arzerra TM 54 dosing cohorts 54 AP# [003] 54 ABRAXANE TM 54 novel histone deacetylase 54 CIMZIA TM certolizumab pegol 54 ExCell study 54 Marketing Authorization Application 54 GRAVITAS trial 54 Ovarian PLCO Cancer 54 prospective multicentre 54 PEGINTRON TM 54 personalized cellular immunotherapy 54 Randomized Phase II 54 colesevelam HCl 54 senicapoc 54 HCV SPRINT 54 BETAS 54 Phase III AFFIRM 54 candidate XP# 54 PREOS R 54 relapsed MM 54 Complete Response 54 RGB # 54 velaglucerase alfa 54 BRILINTA 54 VICTOR E1 54 pixantrone NDA 54 RE SURGE 54 docetaxel Taxotere R 54 Crofelemer budesonide foam 54 recurrent metastatic 54 Diabetic Macular Edema 54 Fortigel 54 vismodegib 54 vernakalant hydrochloride 54 TLK# 54 Raptiva R 54 clinicaltrials 54 thymalfasin 54 PROGENSA R 54 CAPACITY trials 54 ILLUMINATE 54 Chemophase 54 PreCISe study 54 XIENCE V Stent System 54 clevidipine 54 Heart Failure Trial 54 orBec 54 APPRAISE 54 Vernakalant 54 PROMUS Element Stent 54 Æterna Zentaris 54 Allovectin 7 r 54 National Oncologic PET 54 APTIVUS r 54 ofatumumab HuMax CD# 54 EGRIFTA TM 54 TYGACIL 54 Augment Bone Graft 54 investigational immunotherapy 54 HCD# [002] 54 CIMZIA TM 54 ENDEAVOR clinical 54 Plenaxis TM 54 Clonicel 54 CEL SCI Phase III 54 T Pred 54 Genasense oblimersen sodium Injection 53 Sular formulation 53 HoFH 53 ATPace TM 53 Kosan Biosciences Incorporated 53 OncoVEX 53 Phase 2b clinical trials 53 PLK1 SNALP 53 Arikace 53 pharmacokinetic pharmacodynamic 53 MelaFind ® 53 NASDAQ OSIR 53 prospective multicenter 53 TORISEL 53 LIALDA 53 posaconazole 53 dimebon 53 EOquin 53 Sulonex 53 Allovectin 7 53 dose dose escalation 53 GATTEX TM 53 initiate Phase 1b 53 HCV NS5B polymerase 53 cinacalcet HCl 53 CINTREDEKIN BESUDOTOX 53 evaluating mipomersen 53 Phase #b/#a trial 53 PERSEUS clinical program 53 Vilazodone 53 CTA# Injection 53 Bicifadine 53 Junovan 53 OMS#HP 53 eTag assays 53 hyaluronidase enzyme 53 Pharmacokinetic PK 53 hemostatic efficacy 53 HepaGam B TM 53 TG MV 53 Phase IIb trials 53 Dr. Gabriel Lasala 53 Cerashield 53 Auxilium anticipates 53 XL# XL# XL# XL# 53 JOULFERON 53 PrevOnco ™ 53 novel VDA molecule 53 IRX 2 53 MIVI III 53 ZYBRESTAT fosbretabulin 53 Phase III Pivotal 53 RSD# iv 53 midstage studies 53 Azixa 53 Genta Incorporated OTCBB GETA 53 pharmacokinetic 53 ZYBRESTAT 53 QTinno TM 53 MGd 53 Cloretazine ® 53 controlled multicenter 53 ezogabine 53 Clolar ® 53 highly purified pasteurized 53 Onalta ™ 53 TQT studies 53 CALGB 53 romidepsin 53 CLIRS 53 MyVax R 53 Alocrest 53 trastuzumab Herceptin R 53 cancer neuroendocrine tumor 53 investigational therapies 53 aflibercept 53 PCA3 test 53 MAP# 53 placebo controlled 53 Corlux 53 ApoB SNALP 53 Prospective Randomized 53 mertansine 53 TOCOSOL Camptothecin 53 Lenocta 53 Iluvien ® 53 Celacade TM technology 53 Renal Cell Carcinoma RCC 53 Lung Rx 53 oral iron chelator 53 randomized controlled clinical trials 53 eliglustat tartrate 53 Vicinium TM 53 Curaxin CBLC# 53 recurrent malignant glioma 53 TRANSDUR Sufentanil 53 Canvaxin 53 bioequivalency 53 trial evaluating PRX# 53 ID NCT# 53 preclinical studies 53 romiplostim 53 PROSTASCINT R 53 prespecified 53 GEM OS2 53 MERIT ES 53 HuMax CD4 53 evaluating Actimmune 53 Cloretazine 53 refractory multiple myeloma 53 Aryplase 53 Oncotype DX colon cancer 53 ThermoDox ® 53 PSMA ADC 53 Ketotransdel ® 53 ALN RSV# 53 desvenlafaxine succinate 53 LEP ETU 53 ARIKACE 53 FIRAZYR 53 multicentre randomized 53 oral picoplatin 53 nab paclitaxel 53 inhaled AAT 53 MORAb 53 Hedgehog antagonist 53 MARVEL Trial 53 LEVADEX TM 53 recombinant PSMA vaccine 53 velafermin belinostat 53 NDA Submission 53 Hyphanox 53 Nasdaq DVAX 53 Oral NKTR 53 fosbretabulin 53 tezampanel 53 LEVADEX ™ 53 BAY #-# 53 Trofex 53 vilazodone 53 Phase 2a clinical trials 53 LibiGel testosterone gel 53 PEG SN# 53 BEMA TM Fentanyl 53 pain palliation 53 severe gastroparesis 53 LibiGel 53 Phase IIb Clinical Trial 53 BCX# 53 delivers fluocinolone acetonide FA 53 reslizumab 53 Phase III randomized controlled 53 controlled multicenter Phase 53 tanespimycin 53 Azedra TM 53 ACUITY trial 53 PRE SURGE 53 Pharmion Corporation 53 celgosivir 53 brentuximab vedotin SGN 53 trials RCTs 53 MONOVISC 53 EMPOWER TM 53 Topical Interferon Alpha 2b 53 satraplatin 53 Bezielle 53 Betaferon ® 53 Phase IIb randomized 53 CEQ# 53 pharmacokinetics PK 53 Taxotere ® 53 AVASTIN 53 APTIVUS 53 brentuximab vedotin 53 placebo controlled trials 53 Biologics License Application 53 Phase III Clinical Trial 53 Phase III trials 53 Dextofisopam 53 Fast Track designations 53 PXD# 53 evaluating satraplatin 53 vaginally administered lidocaine 53 Phase III Psoriasis 53 multicenter 53 TMC# C# 53 AZILECT ® 53 Phase lll 53 RSD# 53 bovine thrombin 53 KYNAPID 53 efficacy endpoint 53 adecatumumab MT# 53 HCV protease inhibitor 53 Ketotransdel 53 AGGRASTAT R 53 octreotide implant 53 INCB# [002] 53 ECASS 53 ITAX 53 teriflunomide 53 Tracleer R 53 APF# 53 REOLYSIN ® 53 Plenaxis R 53 multicenter phase 53 RE LY trial 53 AeroLEF 53 TRITON TIMI 53 SPIRIVA HandiHaler 53 ROTATEQ 53 aleglitazar 53 APTIVUS ritonavir 53 supplemental biologics 53 glufosfamide 53 Cleviprex TM clevidipine 53 pralatrexate injection 53 Solazed 53 anidulafungin 53 Nasdaq VICL 53 Velcade bortezomib 53 Active Biotech NASDAQ OMX 53 pitavastatin 53 FUSILEV ® 53 Alzhemed TM 53 INC# 53 mapatumumab 53 ENESTnd Evaluating Nilotinib Efficacy 53 ONCONASE 53 Sensitivity analyzes 53 Phase 2b Clinical Trial 52 Prolacria 52 SEPET TM 52 IRBS 52 R lenalidomide 52 confirmatory pivotal 52 dacetuzumab SGN 52 Motesanib 52 SPL# Gel vaginal microbicide 52 ICON7 52 telbivudine 52 HuMax EGFr 52 Xanafide 52 liver resection surgeries 52 NCCTG 52 BLOOM DM 52 ONGLYZA 52 randomized clinical 52 Screening Trial DMIST 52 MVax 52 Zenvia 52 DAS# CRP 52 VIVITROL ® 52 randomized controlled clinical 52 TBC# 52 NCT# 52 denosumab oncology 52 JANUVIA 52 treatment naïve genotype 52 telavancin NDA 52 sorafenib tablets 52 dose titration 52 label dose escalation 52 systemic anaplastic large 52 multicenter randomized double 52 multicenter randomized placebo controlled 52 alemtuzumab MS 52 VADT 52 Tectin TM 52 Phase III ALLEGRO 52 requiring Asthmatx 52 placebo controlled studies 52 lenalidomide Revlimid R 52 amrubicin 52 ISENTRESS 52 multicenter trials